Key result
Among stroke patients without previous aspirin therapy, normal LDL-C levels were associated with a 4-fold increased mortality risk at 24 months.
Why the study?
The link between LDL-C and stroke risk remains controversial, and few studies have evaluated the effect of LDL-C on survival after stroke under the influence of previous aspirin therapy.
Do normal LDL-C levels affect survival and risk of recurrent stroke in stroke patients without previous aspirin therapy?
Cohort (n=342)
Do normal LDL-C levels affect survival and risk of recurrent stroke in stroke patients without previous aspirin therapy?
Normal LDL-C levels may be associated with worse survival and higher recurrence risk in stroke patients who were not previously on aspirin therapy.
Answers are grounded in this paper and cite their sources.
Should not alter lipid or antiplatelet decisions after stroke; leaves open an aspirin–LDL-C interaction that requires prospective confirmation.
Background: The link between low-density lipoprotein cholesterol (LDL-C) and stroke risk remains controversial and few studies have evaluated the effect of LDL-C after stroke survival.Aims: We assessed the hypothesis proposing the effect of LDL-C on the outcome of stroke patients under the influence of previous Aspirin Therapy.Methods: Associations between LDL-C and outcomes. The effect of LDL cholesterol on stoke outcome was evaluated using Kaplan-Meier methodology, log-rank test, Cox proportional hazard models and Bootstrap Analysis.Results: In a cohort of 342 cases, we observed that among stroke patients with no record of previous aspirin therapy LDL-C levels within recommended range (nLDL-C) are associated to a poor overall survival on (p < 0.001, log-rank test) leading to a 4-fold increased mortality risk in both timeframes of 12 (HR 4.45, 95% CI 1.55–12.71; p = 0.004) or 24 months (HR 4.13, 95%CI 1.62–10.50;p = 0.003) after the first event of stroke. Moreover, modelling the risk of a second event after the first stroke in the timeframe of 24 months demonstrated a predictive capacity for nLDL-C plasmatic levels (HR 3.94, 95%CI 1.55–10.05; p = 0.004) confirmed by Bootstrap analysis (p = 0.003; 1000 replications). In a further step, the inclusion of LDL-C in simulating models equations to predict the risk of a second event in the timeframe of 12 months increased nearly 20% the predictive ability (c-index from 0.763 to 0.956).Conclusion: A worse outcome was seen in stroke patients with normal levels of LDLC, but this finding was restricted to patients not under previous aspirin therapy.
No takes yet. Share an insight, caveat, or question.
Freitas-Silva et al. (2020) conducted a cohort in Stroke (n=342). Normal levels of LDL-C (nLDL-C) was evaluated on Mortality risk at 24 months (HR 4.13, 95% CI 1.62-10.50, p=0.003). Among stroke patients without previous aspirin therapy, normal LDL-C levels were associated with a 4-fold increased mortality risk at 24 months.
Synapse has enriched 10 related papers. Consider them for comparative context: